HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Givaudan eyes growth in Brazil

This article was originally published in The Rose Sheet

Executive Summary

Swiss flavor and fragrance firm unveiled its five-year plan in Zurich Aug 31, indicating that developing markets will play an increasing role in corporate growth. Givaudan expects Brazil to be largest-value market for fine fragrance by 2014, outpacing the U.S., based on Euromonitor data. Company recently opened a Creative Center in Brazil and plans to expand its creative resources elsewhere in Latin America. Developing markets currently account for 41% of Givaudan's overall sales and are expected to contribute 50% of sales by 2015. Revenue for the first half of 2010 rose 10.5% compared with the prior-year period, driven by sales of consumer products and increased flavors sales in Latin America, Givaudan says. Firm's overall objective is to grow organically between 4.5% and 5.5% annually, based on assumed market growth of 2% to 3%, and to continue our path of market share gain over the next five years," CEO Gilles Andrier states in a company release

You may also be interested in...



The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy

ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.

US FDA’s 2020 Approvals: A Deep Pipeline, And More Of The Expected

Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).

Gene Therapy Approvals By US FDA Could Double In 2020

CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.

UsernamePublicRestriction

Register

RS017171

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel